Navigation Links
Gerresheimer Discontinues Marginal Operations
Date:6/18/2008

DUSSELDORF, Germany, June 18 /PRNewswire-FirstCall/ --

- Sale of Consumer Healthcare Business

- Concentration on Core Business of Pharmaceutics and Life Science

Gerresheimer AG, the leading manufacturer of glass and plastic products for the pharma & life science industry, is selling its consumer healthcare business. As previously announced, the Dusseldorf company is thereby discontinuing operations which are not part of the core business of pharmaceutics and life science.

"The consumer healthcare business did not fit in with our strategy of focussing on the fields of pharmaceutics and life science. In addition, because of the lack of synergies with the core business, our return requirements for the consumer healthcare business were not fulfilled," says Gerresheimer CEO Dr. Axel Herberg.

The consumer healthcare business, which comprises the production of toothbrushes and other interdental articles and most recently achieved annual sales of EUR24m, was part of the Wilden Group, which was acquired in January 2007. The purchaser is the Krallmann Group. Through the acquisition, Krallmann intends to expand its own plastic processing division and to continue the business under the traditional "Interbros" trademark. The transaction takes place with effect on 1 June 2008. The contractual parties have agreed to keep further details confidential.

Early this year, Gerresheimer already discontinued the marginal business of aluminium packaging with sales of EUR3.3m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharma-ceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press Contact Investor Relations

Burkhard Lingenberg Anke Linnartz

Director Corporate PR & Marketing Director Corporate Investor Relations

Telephone +49-211-6181-250 Telephone +49-211-6181-314

Telefax +49-211-6181-241 Telefax +49-211-6181-121

E-mail E-mail

b.lingenberg@gerresheimer.com a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moodys Raises Rating for Gerresheimer
2. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
3. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
4. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
5. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
6. Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
7. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
8. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
9. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
10. Medimetriks Pharmaceuticals, Inc. Begins Operations
11. Kendle Appoints Patricia Williams Vice President, Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):